quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·154d
PRRelease
Jyong Biotech Ltd. logo

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

MENS· Jyong Biotech Ltd.
Health Care
Original source

Companies

  • MENS
    Jyong Biotech Ltd.
    Health Care

Related

  • INSIDER9d
    SEC Form 3 filed by new insider Zhang Wei (Vivi)
  • INSIDER15d
    SEC Form 3 filed by new insider Kuo Fu-Feng
  • INSIDER22d
    SEC Form 3 filed by new insider Hsu Ming Tsan
  • INSIDER22d
    SEC Form 3 filed by new insider Hsu Feng-Lin
  • INSIDER22d
    SEC Form 3 filed by new insider Hsu Feng-Lin
  • INSIDER22d
    SEC Form 3 filed by new insider Fan Hung-Shu
  • INSIDER22d
    SEC Form 3 filed by new insider Chi Pang-Chieh
  • PR27d
    Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022